NewLimit

NewLimit is a biotechnology startup combining AI, genomics, and epigenetic reprogramming to develop medicines targeting age-related diseases and extending healthy human lifespan

Total funding
$683
Stage
Series C
Employees
11–50

Company Overview

NewLimit is a biotechnology company developing medicines designed to restore youthful function in aging cells and treat age-related diseases. Founded by Brian Armstrong, Blake Byers, and Jacob Kimmel, the company combines epigenetic reprogramming, functional genomics, large-scale biological experiments, and machine learning to discover potential therapeutic candidates.

QueryFeedz Insight

NewLimit sits at the intersection of biotechnology, AI-driven drug discovery, and longevity research. Rather than developing a general-purpose anti-aging product, the company is pursuing therapeutic programs designed to restore specific functions in aging cells. Its platform combines machine-learning predictions with large-scale experimental validation to search for epigenetic interventions that may improve cellular function.

Funding & Investors

Latest funding
$435
Latest round
Series C
Latest funding date
June 2026

Investors

  • Founders Fund (lead investor),
  • Thrive Capital,
  • Greenoaks,
  • Quiet Capital,
  • Kleiner Perkins,
  • Abstract, Nat Friedman and Daniel Gross,
  • Valor Equity Partners,
  • Eli Lilly Ventures,
  • Human Capital,
  • and other participating investors.

Founders

  • Brian Armstrong — Co-Founder and Board Director; also Co-Founder and CEO of Coinbase. Blake Byers — Co-Founder; scientist and investor. Jacob C. Kimmel — Co-Founder and CEO; computational biologist with a background in stem-cell biology and epigenetic reprogramming.